Drug Target Review – Issue #1 2014

In Issue #1 2014 of Drug Target Review:

• Foreword: Enabling the development of new medicines
  Guido Rasi, Executive Director, European Medicines Agency
• GPCRs: Building GPCR screening cascades for lead generation
  Niklas Larsson, Associate Principle Scientist, Discovery Sciences Function / Erik Ryberg, Associate Principal Scientist, Cardiovascular and Metabolic Diseases Function / Linda Sundström, Team Leader – Screening Team, Discovery Sciences Function / Lovisa Frostne, Team Leader, Bioscience Department within Respiratory, Inflammation and Autoimmune iMed Function, AstraZeneca R&D
• Collaboration: Academia Big Pharma collaboration in drug development
  Professor Sir Mark Pepys FRS FMedSci, Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, Division of Medicine, Royal Free Campus, University College London
• Screening: Targeting the ubiquitinproteasome system
  Kenji Schorpp, Scientist and Kamyar Hadian, Head of Assay Development and Screening Platform, Molecular Toxicology and Pharmacology, Helmholtz Zentrum München
• Screening: Heat shock proteins: A high content assay opportunity to measure cellular stress response
  Christophe Antczak, Assistant Director, Balajee Somalinga, Senior Research Scientist and Hakim Djaballah, Director, HTS Core Facility at Memorial Sloan-Kettering Cancer Center
• Cancer Biomarkers: Oncology biomarkers in clinical practice – a new horizon
  Semira Sheikh, Heidi Olzscha and Nicholas B. La Thangue, Laboratory of Cancer Biology, Department of Oncology, University of Oxford
• Genomics: The therapeutic potential of RNA directed epigenetic regulation of transcription
  Kevin V. Morris, Biotechnology and Biomedical Sciences, University of New South Wales and Department of Molecular and Experimental Medicine, The Scripps Research Institute
• Genomics: Drug resistance mechanisms and target selection in disease treatment strategies
  Bhupinder Bhullar, Laboratory Director, Novartis Institute for Biomedical Research
• Marine Drug Discovery: Realising the potential of therapeutics from marine sources – Lessons from Big Pharma
  Marcel Jaspars, Marine Biodiscovery Centre, University of Aberdeen
• Target Validation: Validating molecular targets in preclinical drug discovery
  Isabella Gashaw, Senior Scientist/Group Leader, Hematology Research Department / Khusru Asadullah, Vice President and Head of Global Biomarkers / Martin Bechem, Senior Vice President, Cardiology & Hematology Therapeutic Research Group and Karl Ziegelbauer, Senior Vice President of Global Drug Discovery, Therapeutic Research Group Oncology/Gynecological Therapy, Bayer Global Drug Discovery, Bayer HealthCare
• Nuclear Magnetic Resonance: NMR as a tool for chemokine inhibitor discovery
  Brian F. Volkman, Department of Biochemistry, Medical College of Wisconsin